Organogenesis (NASDAQ:ORGO) Shares Down 5.8% - Time to Sell?

Organogenesis Holdings Inc. (NASDAQ:ORGO - Get Free Report)'s stock price fell 5.8% during trading on Wednesday . The stock traded as low as $5.02 and last traded at $4.92. 202,237 shares were traded during mid-day trading, a decline of 81% from the average session volume of 1,088,569 shares. The stock had previously closed at $5.22.

Wall Street Analyst Weigh In

Separately, Morgan Stanley lifted their price objective on shares of Organogenesis from $4.00 to $6.00 and gave the stock an "equal weight" rating in a research report on Wednesday, March 5th.

Organogenesis Price Performance

The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21. The stock has a 50-day simple moving average of $4.21 and a 200 day simple moving average of $3.58. The stock has a market capitalization of $570.73 million, a price-to-earnings ratio of -75.00 and a beta of 1.66.

Insider Transactions at Organogenesis

In other Organogenesis news, Director Michael Joseph Driscoll sold 25,000 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total value of $127,500.00. Following the completion of the sale, the director now directly owns 166,879 shares of the company's stock, valued at $851,082.90. The trade was a 13.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 36.90% of the company's stock.

Remove Ads

Institutional Investors Weigh In On Organogenesis

Several institutional investors and hedge funds have recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC increased its position in Organogenesis by 16.5% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 39,159 shares of the company's stock worth $125,000 after buying an additional 5,551 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Organogenesis by 2.8% during the 4th quarter. Millennium Management LLC now owns 208,420 shares of the company's stock valued at $667,000 after acquiring an additional 5,765 shares during the last quarter. ProShare Advisors LLC raised its stake in shares of Organogenesis by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 20,329 shares of the company's stock valued at $65,000 after acquiring an additional 6,689 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Organogenesis by 7.1% in the 4th quarter. Rhumbline Advisers now owns 115,266 shares of the company's stock valued at $369,000 after acquiring an additional 7,621 shares in the last quarter. Finally, State Street Corp lifted its holdings in Organogenesis by 0.6% in the 3rd quarter. State Street Corp now owns 1,459,767 shares of the company's stock worth $4,175,000 after purchasing an additional 9,090 shares during the last quarter. Institutional investors and hedge funds own 49.57% of the company's stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.